Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A topical combination regimen consisting of diltiazem, a benzothiazepine calcium channel blocker, and fusidic acid, a steroid-like antibiotic. Diltiazem is used topically to promote local vasodilation and reduce muscle tone, which can enhance blood flow to wounded tissue and accelerate healing. Fusidic acid provides broad-spectrum antibacterial activity, particularly against Gram-positive organisms like *Staphylococcus aureus*, to prevent surgical site infections. This specific combination is being investigated for its efficacy in improving episiotomy healing, reducing pain, and preventing infection following childbirth.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on diltiazem + fusidic acid.